Merck Aggrastat Plus Heparin Shows Short-Term Benefit - Advisory Cmte.
Executive Summary
Merck's Aggrastat combined with heparin shows efficacy in the prevention of early events in patients with acute coronary syndrome, FDA's Cardiovascular & Renal Drugs Advisory Committee agreed April 10.